Similarly, another phase-2 study of a humanized monoclonal antibody, gosuranemab, which targets the N terminal region of tau, also failed to meet its primary endpoint of slowing the cognitive decline after 52 weeks. This evidence concerns the gene MAPT and Mental deterioration.